All In Biotech

Drug Trial Radar · NCT07927556

A Phase II Clinical Trial to Evaluate the Efficacy and Safety of QLS1410 Tablets in Patients With Uncontrolled Hypertension Who Are Receiving One or More Background Drug Treatments

A Randomized, Double-blind, Placebo-controlled, Multicenter Phase II Study to Evaluate the Efficacy and Safety of QLS1410 Tablets in Patients With Uncontrolled Hypertension (Including Resistant Hypertension) Who Are Being Treated With One or More Antihypertensive Medications.

Last checked: Nov 19, 2026Latest source record: Nov 10, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruitingPivotal-lookingRandomized with 260 participants. This is a heuristic, not a regulatory label.

Status

Not yet recruiting

Enrollment

260

Planned (sponsor's estimate)

Start

Nov 2026

Primary completion

Dec 2027

Study completion Jan 2028

Sponsor

Lead sponsor
Qilu Pharmaceutical Co., Ltd.Industry
Sponsor type
Industry
First posted
Nov 10, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The goal of this clinical trial is to evaluate the efficacy and safety of multiple dose strengths of QLS1410 in patients with uncontrolled hypertension.

Conditions

  • Uncontrolled Hypertension

Interventions

  • Dose 1 of QLS1410Drug

    Patients will take oral tablets of QLS1410 once daily (QD) for 12 weeks

  • Dose 2 of QLS1410Drug

    Patients will take oral tablets of QLS1410 once daily (QD) for 12 weeks.

  • Dose 3 of QLS1410Drug

    Patients will take oral tablets of QLS1410 once daily (QD) for 12 weeks.

  • PlaceboDrug

    Matching placebo tablet administered orally, once daily (QD).

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Primary efficacy endpointTime frame: At week 12

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.